Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.
- 1START Madrid-FJD, Early Phase Clinical Trials Unit, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain.
- 2Medical Oncology Department, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria FJD (IIS-FJD), Madrid, Spain.
- 3Biostatistics Unit, Hospital Universitario Fundación Jiménez Díaz, Instituto de Investigación Sanitaria FJD (IIS-FJD), Madrid, Spain.
Abstract
Atezolizumab dose selection was supported by linear pharmacokinetics, absence of a maximum tolerated dose, and trough concentrations exceeding the preclinical receptor saturation target. In the Project Optimus era, we explored whether higher body weight-normalized administered dose was associated with improved outcomes in the original phase I dataset. We assessed 660 patients from the first-in-human PCD4989g study (NCT01375842) separately in the dose-escalation (weight-adjusted) and dose-expansion (fixed 1200 mg) cohorts. Patients were grouped as ≤15 or >15 mg/kg. Sensitivity analyses modeled dose continuously and sequentially excluded individual tumor types. Outcomes were overall survival (OS), progression-free survival (PFS), objective response rate, and grouped immune-mediated adverse events. All analyses were exploratory; no equivalence or noninferiority hypothesis was tested. In the dose-escalation cohort (N = 431), median OS was 15.4 compared with 16.1 months and median PFS was 2.1 compared with 2.7 months; adjusted models showed no improvement with higher normalized dose. In the fixed-dose cohort (N = 229), median OS was 10.1 compared with 7.4 months and median PFS was 1.4 months in both groups. Higher normalized dose was associated with shorter OS in the multivariable model (hazard ratio 1.679, 95% confidence interval 1.186-2.377) but this attenuated after excluding breast cancer. Pneumonitis was numerically more frequent at >15 mg/kg, although events were sparse. Higher normalized atezolizumab dose was not associated with improved outcomes. Substantial clinical and tumor-type imbalances preclude causal, equivalence, or noninferiority conclusions. These findings support prospective randomized dose-optimization studies rather than routine dose modification.
Related
- Early antibiotic exposure, but not late exposure, negatively affects the clinical outcomes of first-line atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma
- Baseline Host Biomarkers and Six-Month Sustained Drug-Free Status After Atezolizumab–Bevacizumab for Hepatocellular Carcinoma: Exploratory Clinical Stratification Using PAN-DF Score
- Clinical features and outcomes of atezolizumab-associated encephalitis
- Surgical Revision of Deep Brain Stimulation After Suboptimal Clinical Outcomes: A Systematic Review and Exploratory Meta-analysis
- Short-Term Clinical Outcomes of Ready-Made Soft Splints Versus Digitally Fabricated, Customized Hard Stabilization Splints in Temporomandibular Disorders: An Exploratory Randomized Study
BibTeX
@article{moreno2026normalized,
title = {{Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.}},
author = {V Moreno and M Dorta and A Rueda and P Villalba and E García-Lorenzo and M Pedregal and B Doger and I Mahíllo-Fernández},
journal = {Immuno-oncology technology},
year = {2026},
month = oct,
doi = {10.1016/j.iotech.2026.101612},
url = {https://europepmc.org/article/MED/42999628},
note = {CC BY-NC-ND},
}
RIS
TY - JOUR
TI - Normalized administered atezolizumab dose and clinical outcomes in advanced solid tumors: an exploratory analysis of the phase I PCD4989g study.
AU - V Moreno
AU - M Dorta
AU - A Rueda
AU - P Villalba
AU - E García-Lorenzo
AU - M Pedregal
AU - B Doger
AU - I Mahíllo-Fernández
PY - 2026
DA - 2026/10/29
JO - Immuno-oncology technology
DO - 10.1016/j.iotech.2026.101612
UR - https://europepmc.org/article/MED/42999628
AB - Atezolizumab dose selection was supported by linear pharmacokinetics, absence of a maximum tolerated dose, and trough concentrations exceeding the preclinical receptor saturation target. In the Project Optimus era, we explored whether higher body weight-normalized administered dose was associated with improved outcomes in the original phase I dataset. We assessed 660 patients from the first-in-human PCD4989g study (NCT01375842) separately in the dose-escalation (weight-adjusted) and dose-expansion (fixed 1200 mg) cohorts. Patients were grouped as ≤15 or >15 mg/kg. Sensitivity analyses modeled dose continuously and sequentially excluded individual tumor types. Outcomes were overall survival (OS), progression-free survival (PFS), objective response rate, and grouped immune-mediated adverse events. All analyses were exploratory; no equivalence or noninferiority hypothesis was tested. In the dose-escalation cohort (N = 431), median OS was 15.4 compared with 16.1 months and median PFS was 2.1 compared with 2.7 months; adjusted models showed no improvement with higher normalized dose. In the fixed-dose cohort (N = 229), median OS was 10.1 compared with 7.4 months and median PFS was 1.4 months in both groups. Higher normalized dose was associated with shorter OS in the multivariable model (hazard ratio 1.679, 95% confidence interval 1.186-2.377) but this attenuated after excluding breast cancer. Pneumonitis was numerically more frequent at >15 mg/kg, although events were sparse. Higher normalized atezolizumab dose was not associated with improved outcomes. Substantial clinical and tumor-type imbalances preclude causal, equivalence, or noninferiority conclusions. These findings support prospective randomized dose-optimization studies rather than routine dose modification.
SN - 2590-0188
ER -